Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2014 2
2015 3
2016 4
2017 6
2018 5
2019 7
2020 12
2021 10
2022 11
2023 15
2024 5

Text availability

Article attribute

Article type

Publication date

Search Results

66 results

Results by year

Filters applied: . Clear all
Page 1
Ciltacabtagene autoleucel in patients with relapsed/refractory multiple myeloma: CARTITUDE-1 (phase 2) Japanese cohort.
Ri M, Suzuki K, Ishida T, Kuroda J, Tsukamoto T, Teshima T, Goto H, Jackson CC, Sun H, Pacaud L, Fujikawa E, Yeh TM, Hatayama T, Aida K, Sunagawa Y, Iida S. Ri M, et al. Among authors: tsukamoto t. Cancer Sci. 2022 Dec;113(12):4267-4276. doi: 10.1111/cas.15556. Epub 2022 Oct 7. Cancer Sci. 2022. PMID: 36052883 Free PMC article. Clinical Trial.
Tumour-derived exosomes promote the induction of monocytic myeloid-derived suppressor cells from peripheral blood mononuclear cells by delivering miR-106a-5p and miR-146a-5p in multiple myeloma.
Mizuhara K, Shimura Y, Tsukamoto T, Kanai A, Kuwahara-Ota S, Yamaguchi J, Muramatsu A, Okamoto H, Taminishi-Katsuragawa Y, Kawaji-Kanayama Y, Isa R, Mizutani S, Inaba T, Kuroda J. Mizuhara K, et al. Among authors: tsukamoto t. Br J Haematol. 2023 Nov;203(3):426-438. doi: 10.1111/bjh.19049. Epub 2023 Aug 16. Br J Haematol. 2023. PMID: 37584109
Triple targeting of RSK, AKT, and S6K as pivotal downstream effectors of PDPK1 by TAS0612 in B-cell lymphomas.
Katsuragawa-Taminishi Y, Mizutani S, Kawaji-Kanayama Y, Onishi A, Okamoto H, Isa R, Mizuhara K, Muramatsu A, Fujino T, Tsukamoto T, Shimura Y, Taniwaki M, Miyagawa-Hayashino A, Konishi E, Kuroda J. Katsuragawa-Taminishi Y, et al. Among authors: tsukamoto t. Cancer Sci. 2023 Dec;114(12):4691-4705. doi: 10.1111/cas.15995. Epub 2023 Oct 15. Cancer Sci. 2023. PMID: 37840379 Free PMC article.
Gastric Myeloid Sarcoma Mimicking a Scirrhous Gastric Cancer.
Taminishi-Katsuragawa Y, Shimura Y, Inoue Y, Matsumura-Kimoto Y, Tsukamoto T, Mizutani S, Kobayashi T, Takeda-Miyata N, Nishimura A, Takatsuka K, Kuroda J. Taminishi-Katsuragawa Y, et al. Among authors: tsukamoto t. Intern Med. 2022 Apr 15;61(8):1231-1235. doi: 10.2169/internalmedicine.7986-21. Epub 2021 Oct 5. Intern Med. 2022. PMID: 34615821 Free PMC article.
Toward further simplification of elotuzumab therapy by subcutaneous administration.
Shimura Y, Tsukamoto T, Yamaguchi J, Kuwahara-Ota S, Isa R, Nishiyama D, Kobayashi T, Horiike S, Suzuki A, Kuroda J. Shimura Y, et al. Among authors: tsukamoto t. Int J Hematol. 2020 Sep;112(3):427-428. doi: 10.1007/s12185-020-02942-6. Epub 2020 Jul 13. Int J Hematol. 2020. PMID: 32656639 No abstract available.
The Rationale for the Dual-Targeting Therapy for RSK2 and AKT in Multiple Myeloma.
Isa R, Horinaka M, Tsukamoto T, Mizuhara K, Fujibayashi Y, Taminishi-Katsuragawa Y, Okamoto H, Yasuda S, Kawaji-Kanayama Y, Matsumura-Kimoto Y, Mizutani S, Shimura Y, Taniwaki M, Sakai T, Kuroda J. Isa R, et al. Among authors: tsukamoto t. Int J Mol Sci. 2022 Mar 8;23(6):2919. doi: 10.3390/ijms23062919. Int J Mol Sci. 2022. PMID: 35328342 Free PMC article.
Pretreatment serum level of interleukin-6 predicts carfilzomib-induced hypertension in relapsed/refractory multiple myeloma.
Muramatsu A, Kobayashi T, Kawaji-Kanayama Y, Uchiyama H, Sasaki N, Uoshima N, Nakao M, Takahashi R, Shimura K, Kaneko H, Kiyota M, Wada K, Chinen Y, Hirakawa K, Fuchida SI, Shimazaki C, Mizutani S, Tsukamoto T, Shimura Y, Taniwaki M, Teramukai S, Kuroda J; Kyoto Clinical Hematology Study Group (KOTOSG) Investigators. Muramatsu A, et al. Among authors: tsukamoto t. Leuk Lymphoma. 2022 Jul;63(7):1678-1685. doi: 10.1080/10428194.2022.2038373. Epub 2022 Feb 11. Leuk Lymphoma. 2022. PMID: 35147475
Iguratimod triggers the relapse of methotrexate-associated lymphoproliferative disorder.
Nagata H, Kuriyama K, Nishikawa R, Ohshiro M, Yamamoto-Sugitani M, Fujimoto-Hirakawa Y, Matsumoto Y, Iwai T, Tsukamoto T, Mizutani S, Shimura Y, Kobayashi T, Fukuda W, Uchiyama H, Kuroda J. Nagata H, et al. Among authors: tsukamoto t. Ann Hematol. 2021 Nov;100(11):2849-2850. doi: 10.1007/s00277-021-04645-2. Epub 2021 Aug 22. Ann Hematol. 2021. PMID: 34420071 No abstract available.
66 results